Paul A. Bunn

52.2k citations

496 papers · 35.3k indexed · 13 hit papers · h-index 96

Oncology top 0.02%
Pulmonary and Respiratory Medicine top 0.02%
Molecular Biology top 0.2%
Immunology top 0.1%
Epidemiology top 0.5%

Co-authors: John D. Minna Adi F. Gazdar Robert C. Gallo Wilbur A. Franklin Francis W. Ruscetti Bernard J. Poiesz Fred R. Hirsch Karen Kelly
Topics: Lung Cancer Treatments and Mutations (208 papers)Lung Cancer Research Studies (149 papers)Lung Cancer Diagnosis and Treatment (88 papers)
Cited by: Oncology Pulmonary and Respiratory Medicine Immunology
Journals: Nature Science New England Journal of Medicine
Partner nations: United States Spain Italy

In The Last Decade

Paul A. Bunn

483 papers receiving 33.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma

1980 4.1k citations Adi F. Gazdar, Paul A. Bunn et al. profile →
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy

2004 1.9k citations Paul A. Bunn et al. Journal of Clinical Oncology profile →
Epidermal Growth Factor Receptor in Non–Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on Prognosis

2003 1.2k citations Fred R. Hirsch, Marileila Varella‐Garcia et al. Journal of Clinical Oncology profile →
Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial

2001 923 citations Karen Kelly, Paul A. Bunn et al. Journal of Clinical Oncology profile →
Determination of the immunoreactive function of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess

1984 845 citations Paul A. Bunn et al. profile →
Small-cell lung cancer: what we know, what we need to know and the path forward

2017 581 citations Adi F. Gazdar, Paul A. Bunn et al. profile →
Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer

2006 570 citations Fred R. Hirsch, Marileila Varella‐Garcia et al. Journal of Clinical Oncology profile →
Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer

2012 508 citations Paul A. Bunn, Dara L. Aisner et al. profile →
Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer

2006 500 citations Paul A. Bunn, Corey J. Langer et al. Journal of Clinical Oncology profile →
Specific Chromosome Defect Associated with Human Small-Cell Lung Cancer: Deletion 3p(14-23)

1982 381 citations J. Whang‐Peng, Paul A. Bunn et al. profile →
CNS metastases in small cell bronchogenic carcinoma.Increasing frequency and changing pattern with lengthening survival

1979 361 citations Paul A. Bunn, Mary J. Matthews et al. Cancer profile →
New and emerging targeted treatments in advanced non-small-cell lung cancer

2016 359 citations Fred R. Hirsch, Paul A. Bunn et al. profile →
Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions

2023 179 citations Paul A. Bunn, Fred R. Hirsch et al. profile →

Peers

Countries citing papers authored by Paul A. Bunn

Since Specialization

Citations

This map shows the geographic impact of Paul A. Bunn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul A. Bunn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul A. Bunn more than expected).

Fields of papers citing papers by Paul A. Bunn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul A. Bunn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul A. Bunn. The network helps show where Paul A. Bunn may publish in the future.

Co-authorship network of co-authors of Paul A. Bunn

This figure shows the co-authorship network connecting the top 25 collaborators of Paul A. Bunn. A scholar is included among the top collaborators of Paul A. Bunn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul A. Bunn. Paul A. Bunn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Calls to action on lung cancer management and research 2024 ·The Oncologist ·(unknown),Fred R. Hirsch,Paul A. Bunn,Peter Ujházy,(unknown),Christine D. Berg,David P. Carbone,Balázs Halmos,Harpreet Singh,Hossein Borghaei,Andrea Ferris,Corey J. Langer,Sanja Đačić,Tony Mok,Solange Peters,Bruce E. Johnson	1
2	A Randomized Phase II Trial of Pioglitazone for Lung Cancer Chemoprevention in High-Risk Current and Former Smokers 2019 ·Cancer Prevention Research ·Robert L. Keith,Patrick J. Blatchford,Daniel T. Merrick,Paul A. Bunn,(unknown),Lori D. Dwyer‐Nield,(unknown),Mark W. Geraci,York E. Miller	19
3	Resistance Mechanisms to Targeted Therapies in ROS1 + and ALK + Non–small Cell Lung Cancer 2018 ·Clinical Cancer Research ·Caroline E. McCoach,Anh T. Le,Katherine Gowan,Kenneth A. Jones,Laura Schubert,Andrea E. Doak,Adriana Estrada‐Bernal,(unknown),Daniel T. Merrick,Paul A. Bunn,(unknown),Rafał Dziadziuszko,Marileila Varella‐Garcia,Dara L. Aisner,D. Ross Camidge,Robert C. Doebele	179
4	Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo 2016 ·Molecular Cancer Therapeutics ·Barbara A. Helfrich,Jihye Kim,Dexiang Gao,Daniel C. Chan,Zhiyong Zhang,Aik Choon Tan,Paul A. Bunn	83
5	AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non–Small Cell Lung Cancer Cells Following EGFR Inhibition 2016 ·Clinical Cancer Research ·(unknown),Barbara A. Helfrich,Matias Casás‐Selves,Alwin G. Schuller,Shaun Grosskurth,Jihye Kim,Aik Choon Tan,Daniel C. Chan,Zhiyong Zhang,Vadym Zaberezhnyy,Paul A. Bunn,James DeGregori	50
6	Persistence of Bronchial Dysplasia Is Associated with Development of Invasive Squamous Cell Carcinoma 2015 ·Cancer Prevention Research ·Daniel T. Merrick,Dexiang Gao,York E. Miller,Robert L. Keith,Anna E. Barón,William J. Feser,Timothy C. Kennedy,Patrick J. Blatchford,(unknown),Fred R. Hirsch,Lynn E. Heasley,Paul A. Bunn,Wilbur A. Franklin	24
7	FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies 2014 ·Clinical Cancer Research ·Murry W. Wynes,Trista K. Hinz,Dexiang Gao,Michael L. Martini,Lindsay A. Marek,Kathryn E. Ware,(unknown),Diana Böhm,Sven Perner,Barbara A. Helfrich,Rafał Dziadziuszko,Jacek Jassem,Szymon Wojtylak,Aleksandra Sejda,Joseph M. Gozgit,Paul A. Bunn,D. Ross Camidge,Aik Choon Tan,Fred R. Hirsch,Lynn E. Heasley	125
8	Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium 2014 ·Cancer ·Liza C. Villaruz,Mark A. Socinski,Shira Abberbock,Lynne D. Berry,Bruce E. Johnson,David J. Kwiatkowski,A. John Iafrate,Marileila Varella‐Garcia,Wilbur A. Franklin,D. Ross Camidge,Lecia V. Sequist,Eric B. Haura,(unknown),Brenda F. Kurland,Kelly Kugler,John D. Minna,Paul A. Bunn,Mark G. Kris	94
9	Exploring the relationship between technology use, hearing help-seeking, and hearing aid outcomes in older adults 2014 ·International Journal of Audiology ·(unknown),Paul A. Bunn,Carly Meyer,Asaduzzaman Khan,Louise Hickson	9
10	Endobronchial miRNAs as Biomarkers in Lung Cancer Chemoprevention 2012 ·Cancer Prevention Research ·Céline Mascaux,William J. Feser,(unknown),Anna E. Barón,Christopher D. Coldren,Daniel T. Merrick,Timothy C. Kennedy,(unknown),(unknown),Wilbur A. Franklin,John D. Minna,Paul A. Bunn,York E. Miller,Robert L. Keith,Fred R. Hirsch	12
11	Tankyrase and the Canonical Wnt Pathway Protect Lung Cancer Cells from EGFR Inhibition 2012 ·Cancer Research ·Matias Casás‐Selves,Jihye Kim,Zhiyong Zhang,Barbara A. Helfrich,Dexiang Gao,Christopher C. Porter,(unknown),Paul A. Bunn,Daniel C. Chan,Aik Choon Tan,James DeGregori	109
12	Oral Iloprost Improves Endobronchial Dysplasia in Former Smokers 2011 ·Cancer Prevention Research ·Robert L. Keith,Patrick J. Blatchford,John Kittelson,John D. Minna,Karen Kelly,Pierre P. Massion,Wilbur A. Franklin,Jenny Mao,David O. Wilson,Daniel T. Merrick,Fred R. Hirsch,Timothy C. Kennedy,Paul A. Bunn,Mark W. Geraci,York E. Miller	72
13	The Tissue Is the Issue: Personalized Medicine for Non-Small Cell Lung Cancer 2010 ·Clinical Cancer Research ·Fred R. Hirsch,Murry W. Wynes,David R. Gandara,Paul A. Bunn	58
14	Surgery With or Without Preoperative Paclitaxel and Carboplatin in Early-Stage Non–Small-Cell Lung Cancer: Southwest Oncology Group Trial S9900, an Intergroup, Randomized, Phase III Trial 2010 ·Journal of Clinical Oncology ·Katherine M.W. Pisters,Eric Vallières,John J. Crowley,Wilbur A. Franklin,Paul A. Bunn,Robert J. Ginsberg,Joe B. Putnam,Kari Chansky,David R. Gandara	167
15	Abstract #4775: The selective aurora B kinase inhibitor AZD1152-HQPA inhibits in vitro growth of small cell lung cancer (SCLC) cell lines 2009 ·Cancer Research ·Barbara A. Helfrich,Mariana F. Theodoro,(unknown),Jerry Haney,Lynne Bemis,Paul A. Bunn	1
16	Baseline Gene Expression Predicts Sensitivity to Gefitinib in Non–Small Cell Lung Cancer Cell Lines 2006 ·Molecular Cancer Research ·Christopher D. Coldren,Barbara A. Helfrich,Samir E. Witta,Michio Sugita,Razvan Lapadat,Chan Zeng,(unknown),Wilbur A. Franklin,Fred R. Hirsch,Mark W. Geraci,Paul A. Bunn	107
17	Biological Markers for Non–Small Cell Lung Cancer Patient Selection for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy 2006 ·Clinical Cancer Research ·Paul A. Bunn,Rafał Dziadziuszko,Marileila Varella‐Garcia,Wilbur A. Franklin,Samir E. Witta,Karen Kelly,Fred R. Hirsch	46
18	Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents. 2001 ·PubMed ·Paul A. Bunn,B. Helfrich,(unknown),Wilbur A. Franklin,Marileila Varella‐Garcia,Fred R. Hirsch,Anna E. Barón,Chan Zeng,Daniel C. Chan	131
19	Biology of lung cancer 1998 ·Marcel Dekker eBooks ·Madeleine Kane,Paul A. Bunn	5
20	Cytogenetic abnormalities in patients with cutaneous T-cell lymphomas. 1979 ·Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·J. Whang‐Peng,Paul A. Bunn,Tor Knutsen,GP Schechter,Adi F. Gazdar,Mary J. Matthews,John D. Minna	39

About Paul A. Bunn

Paul A. Bunn is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Dermatology, having authored 496 papers that have together received 35.3k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (208 papers), Lung Cancer Research Studies (149 papers) and Lung Cancer Diagnosis and Treatment (88 papers). The work is most often cited by research in Oncology (16.9k citations), Pulmonary and Respiratory Medicine (14.6k citations) and Immunology (7.1k citations). Paul A. Bunn has collaborated with scholars based in United States, Spain and Italy. Frequent co-authors include John D. Minna, Adi F. Gazdar, Robert C. Gallo, Wilbur A. Franklin, Francis W. Ruscetti, Bernard J. Poiesz, Fred R. Hirsch, Karen Kelly, Marileila Varella‐Garcia and Fred R. Hirsch. Their work appears in journals such as Nature, Science and New England Journal of Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact